Allergen-specific immunotherapy: Regulatory T cells or allergen-specific IgG?

Human Vaccines

Volumn 6, Issue 8, 2010, Pages 673-675

  Kündig, Thomas M ^a   Bachmann, Martin F ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

Allergy; IgG; Immunotherapy; Tregs; Vaccines

Indexed keywords

ALLERGEN; CYTOKINE; FC RECEPTOR IIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ALLERGY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; CYTOKINE RELEASE; DENDRITIC CELL; DESENSITIZATION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MAST CELL; NOTE; REGULATORY T LYMPHOCYTE; SUBCUTANEOUS ALLERGEN SPECIFIC IMMUNOTHERAPY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; URTICARIA;

EID: 77956640255     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.8.12007     Document Type: Note

References (38)

1. Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005; 116:377-83. (Pubitemid 41096546)
2. Verlato G, Corsico A, Villani S, Cerveri I, Migliore E, Accordini S, et al. Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol 2003; 111:1232-8. (Pubitemid 36683675)
3. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351:1225-32.
4. Wuthrich B, Schindler C, Medici TC, Zellweger JP, Leuenberger P. IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss Study on Air Pollution and Lung Diseases in Adults) Team. Int Arch Allergy Immunol 1996; 111:396-402.
5. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
6. Lockey RF. "ARIA": global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 2001; 108:497-9.
7. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Bmj 1991; 302:265-9.
8. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75. (Pubitemid 29372886)
9. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97:579-87. (Pubitemid 26062755)
10. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-7.
11. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6. (Pubitemid 34158289)
12. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86:775-80.
13. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660-77.
14. Stewart GE, 2nd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992; 90:567-78.
15. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 1:1572.
16. Freeman EJ. Vaccination against hay fever: reports of results during the last 3 years. Lancet 1914; 1:1178.
17. Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical properties of human reaginic antibody IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966; 97:75-85.
18. Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967; 13:381-94.
19. Golden DB, Meyers DA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982; 69:489-93. (Pubitemid 12074697)
20. Muller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 1989; 44:412-8.
21. van der Giessen M, Homan WL, van Kernbeek G, Aalberse RC, Dieges PH. Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy. Int Arch Allergy Appl Immunol 1976; 50:625-40.
22. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-51. (Pubitemid 23262381)
23. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFNgamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154:4187-94.
24. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-65.
25. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009; 8:645-60.
26. + T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61.
27. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608-15. (Pubitemid 38264178)
28. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001; 357:752-6. (Pubitemid 32217683)
29. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008; 63:1455-63.
30. + regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008; 29:771-81.
31. Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFNgamma production of T cells. J Allergy Clin Immunol 1999; 103:326-32. (Pubitemid 29095840)
32. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4:313-8.
33. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-34.
34. Jakobsen CG, Bodtger U, Kristensen P, Poulsen LK, Roggen EL. Isolation of high-affinity human IgE and IgG antibodies recognising Bet v1 and Humicola lanuginosa lipase from combinatorial phage libraries. Mol Immunol 2004; 41:941-53. (Pubitemid 39070323)
35. 1 and G4 measured by surface plasmon resonance. Clin Exp Allergy 2005; 35:193-8.
36. + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163:2944-52.
37. Carballido JM, Carballido-Perrig N, Kagi MK, Meloen RH, Wuthrich B, Heusser CH, et al. T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol 1993; 150:3582-91. (Pubitemid 23129739)
38. Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S, et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009; 206:1941-55.